Jia et al., 2025 - Google Patents
Dual responsive magnetic DCR3 nanoparticles: a new strategy for efficiently targeting hepatocellular carcinomaJia et al., 2025
- Document ID
- 17483353690039367014
- Author
- Jia L
- Dai Y
- Xu Y
- Sun H
- Gao H
- Hao H
- Wang L
- Xu J
- Shang J
- Li G
- Xu Y
- Feng L
- Publication year
- Publication venue
- Small
External Links
Snippet
Hepatocellular carcinoma (HCC) is a major cause of cancer deaths globally. Unlike traditional molecularly targeted drugs, magnetically controlled drug delivery to micro/nanorobots enhances precision in targeting tumors, improving drug efficiency and …
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives
- A61K47/48—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates
- A61K47/48769—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates the conjugate being characterized by a special physical or galenical form
- A61K47/48853—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates the conjugate being characterized by a special physical or galenical form the form being a particulate, powder, adsorbate, bead, sphere
- A61K47/48876—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates the conjugate being characterized by a special physical or galenical form the form being a particulate, powder, adsorbate, bead, sphere the form being a solid micro- or nanoparticle having no hollow or gas-filled core
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Sabit et al. | Nanocarriers: a reliable tool for the delivery of anticancer drugs | |
| Kim et al. | Perspectives for improving the tumor targeting of nanomedicine via the EPR effect in clinical tumors | |
| Palzer et al. | Iron oxide nanoparticle-based hyperthermia as a treatment option in various gastrointestinal malignancies | |
| D’Agata et al. | Magnetic nanoparticles in the central nervous system: targeting principles, applications and safety issues | |
| Sun et al. | Gold nanoparticle-induced cell death and potential applications in nanomedicine | |
| de Toledo et al. | Iron oxide magnetic nanoparticles as antimicrobials for therapeutics | |
| Al-Musawi et al. | Design and synthesis of multi-functional superparamagnetic core-gold shell nanoparticles coated with chitosan and folate for targeted antitumor therapy | |
| Tietze et al. | Nanoparticles for cancer therapy using magnetic forces | |
| Munir | Nanomedicine penetration to tumor: challenges, and advanced strategies to tackle this issue | |
| Yang et al. | Preparation of folic acid-conjugated, doxorubicin-loaded, magnetic bovine serum albumin nanospheres and their antitumor effects in vitro and in vivo | |
| Meng et al. | Biomimetic immunomagnetic nanoparticles with minimal nonspecific biomolecule adsorption for enhanced isolation of circulating tumor cells | |
| El-Sherbiny et al. | Magnetic nanoparticles-based drug and gene delivery systems for the treatment of pulmonary diseases | |
| Yang et al. | Pilot study of targeting magnetic carbon nanotubes to lymph nodes | |
| Sheng et al. | Magnetically responsive microbubbles as delivery vehicles for targeted sonodynamic and antimetabolite therapy of pancreatic cancer | |
| Owen et al. | Magnetic targeting of microbubbles against physiologically relevant flow conditions | |
| Jia et al. | Dual responsive magnetic DCR3 nanoparticles: a new strategy for efficiently targeting hepatocellular carcinoma | |
| Simón-Gracia et al. | Peritoneal carcinomatosis targeting with tumor homing peptides | |
| Friedrich et al. | SPIONs and magnetic hybrid materials: Synthesis, toxicology and biomedical applications | |
| Cristofolini et al. | Hybrid polyelectrolyte/Fe3O4 nanocapsules for hyperthermia applications | |
| Levada et al. | Magnetic-assisted treatment of liver fibrosis | |
| Li et al. | Evaluation of tumor treatment of magnetic nanoparticles driven by extremely low frequency magnetic field | |
| Novoselova et al. | Submicron-sized nanocomposite magnetic-sensitive carriers: controllable organ distribution and biological effects | |
| Chen et al. | Augmented EPR effect post IRFA to enhance the therapeutic efficacy of arsenic loaded ZIF-8 nanoparticles on residual HCC progression | |
| Deng et al. | Dual targeting with cell surface electrical charge and folic acid via superparamagnetic Fe3O4@ Cu2–xS for photothermal cancer cell killing | |
| Redolfi Riva et al. | Enhanced in vitro magnetic cell targeting of doxorubicin-loaded magnetic liposomes for localized cancer therapy |